Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma

被引:0
|
作者
Sletnes, KE [1 ]
Holte, H [1 ]
Halvorsen, S [1 ]
Jakobsen, E [1 ]
Wisloff, F [1 ]
Kvaloy, S [1 ]
机构
[1] NORWEGIAN RADIUM HOSP,DEPT ONCOL,OSLO,NORWAY
关键词
coagulation activation; bone marrow harvesting; Hickman-catheter; deep vein thrombosis;
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Evidence of activation of coagulation was sought in serial plasma samples from 25 ABMT candidates with malignant lymphoma admitted for bone marrow harvesting: 10 females and 15 males, median age 41 years (range 27-58 years), Nineteen patients had non-Hodgkin's lymphoma (NHL) and six had Hodgkin's disease, Of those with NHL, 14 had high-grade and five low-grade disease, The plasma levels of markers of activation (prothrombin fragment 1 + 2, thrombin-antithrombin complexes, fibrinopeptide A and fibrinmonomers) increased significantly (P < 0.001) in association with harvesting, Except for fibrinopeptide A, the indicators of activation were still significantly elevated 24 h after marrow aspiration, beta-thromboglobulin, a marker of the platelet release reaction, also increased significantly (P < 0.01), Four out of nine patients in whom a long-term central venous catheter was inserted just after marrow aspiration, developed catheter-related deep vein thrombosis, verified venographically, shortly after harvesting, These results suggest that patients with malignant lymphoma undergoing marrow harvesting develop a hypercoagulable state, and that insertion of a central intravenous catheter immediately after marrow harvesting should be avoided to prevent the development of symptomatic deep vein thrombosis.
引用
收藏
页码:577 / 581
页数:5
相关论文
共 27 条
  • [21] Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF
    Scheid, C
    Reiser, M
    Draube, A
    Josting, A
    Fuchs, M
    Chemnitz, J
    Winter, S
    Schulz, A
    Engert, A
    Diehl, V
    Söhngen, D
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (04): : 411 - 413
  • [22] Comparison of Direct Iliofemoral Stenting Following AngioJet Rheolytic Thrombectomy vs Staged Stenting After AngioJet Rheolytic Thrombectomy Plus Catheter-Directed Thrombolysis in Patients With Acute Deep Vein Thrombosis
    Liu, Guang
    Qin, Jinbao
    Cui, Chaoyi
    Ye, Kaichuang
    Shi, Huihua
    Liu, Xiaobing
    Yin, Minyi
    Huang, Xintian
    Lu, Min
    Jiang, Mier
    Li, Weimin
    Lu, Xinwu
    JOURNAL OF ENDOVASCULAR THERAPY, 2018, 25 (01) : 133 - 139
  • [23] PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION AFTER HIGH-DOSE THERAPY IN PATIENTS WITH MALIGNANT-LYMPHOMA - A RETROSPECTIVE COMPARISON WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    AGER, S
    SCOTT, MA
    MAHENDRA, P
    RICHARDS, EM
    JESTICE, HK
    BORAKS, P
    BAGLIN, TP
    MARCUS, RE
    BONE MARROW TRANSPLANTATION, 1995, 16 (01) : 79 - 83
  • [24] Guidance of Venous Stent Implantation after Catheter-directed Thrombosis in Patients with Acute Left Lower Extremity Deep Venous Thrombosis based on Pressure Gradient Differences between the Iliac Vein and Inferior Vena Cava: A Single-center Retrospective Study
    Che, Haijie
    Liu, Guolong
    Yu, Ying
    Sang, Guifeng
    Zhang, Xiaoming
    ANNALS OF VASCULAR SURGERY, 2019, 59 : 217 - 224
  • [25] AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) AFTER FRACTIONATED TBI (200CGYX6) AND HDARA-C (3 G/M2 X 8) IN 2 PATIENTS WITH RESISTANT T-CELL LYMPHOBLASTIC LYMPHOMA
    FERREMI, P
    MORRICA, B
    ROSSI, G
    BELLETTI, S
    RONCOLI, B
    VERZURA, P
    FRANCESCHINI, F
    MORETTI, L
    IZZI, T
    MAGNO, L
    MARINONE, G
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, : 257 - 257
  • [26] THROMBOPOIETIC EFFECT OF INTERLEUKIN-3 (IL-3) AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN PATIENTS WITH NON-HODGKIN-LYMPHOMA (NHL) OR HODGKINS-DISEASE (HD) - RESULTS FROM A PHASE-III PLACEBO-CONTROLLED STUDY
    FIBBE, WE
    VELLENGA, E
    BEZWODA, WR
    MARANINCHI, D
    HERMANN, R
    DURANT, S
    MARTELLI, M
    PICO, I
    SKLENAR, I
    GIANELLABORRADORI, A
    BLOOD, 1994, 84 (10) : A92 - A92
  • [27] Bispecific antibody fragments with CD20 x CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma
    Brandl, M
    Grosse-Hovest, L
    Holler, E
    Kolb, HJ
    Jung, G
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (08) : 1264 - 1270